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Abstract
Background: Current management for men with lower urinary tract symptoms (LUTS) is a pathway that results in
prostate surgery in a significant proportion. While helpful in relieving benign prostatic obstruction (BPO), surgery
may be ineffective for men suffering from difficulties not relating to BPO. The UPSTREAM trial started recruitment in
October 2014 with the aim of establishing whether a care pathway including urodynamics (a diagnostic tool for
BPO and thus an indication of whether surgery is needed) is no worse for men, in terms of symptomatic outcome,
than one without (routine care).
Methods/design: This analysis plan outlines the main outcomes of the study and specific design choices, such as
non-inferiority margins. The trial is currently recruiting in 26 hospitals across the UK, randomising men to either
urodynamics or routine care, with recruitment set to end on the 31 December 2016. All outcomes will be measured
18 months after randomisation to allow sufficient time for surgical procedures and recovery. The primary outcome
is based on a non-inferiority design with a margin of 1 point on the International Prostate Symptom Score (IPSS)
scale. The key secondary outcome for this trial is surgery rate per arm, which is estimated to be at least 18% lower
in the urodynamics arm. Surgery rates, adverse events, flow rate, urinary symptoms and sexual symptoms are
secondary outcomes to be assessed for superiority. This is an update to the UPSTREAM protocol, which has already
been published in this journal.
Discussion: This a priori statistical analysis plan aims to reduce reporting bias by allowing access to the trial’s
objectives and plans in advance of recruitment end. The results of the trial are expected to be published soon after
the trial end date of 30 September 2018.
Trial registration: ISRCTN registry, ISRCTN56164274. Registered on 8 April 2014.
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Non-inferiority trial
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Introduction
The Urodynamics for Prostate Surgery Trial (UP-
STREAM) is a two-arm trial, which randomises men
with bothersome lower urinary tract symptoms (LUTS),
for whom surgeons would consider offering surgery,
between two treatment pathways. The intervention arm
is a slightly invasive care pathway to see if surgery is
needed based on urodynamic tests with multichannel
cystometry while the control arm is a care pathway
without urodynamics tests (current routine care). The
UPSTREAM trial is a pragmatic, randomised controlled
trial with a non-inferiority primary outcome. More de-
tails concerning the trial’s rationale can be found in the
published protocol [1]. Briefly, the primary aim of the
UPSTREAM trial is to establish whether a treatment
pathway for LUTS that includes urodynamics is no
worse for men, in terms of symptom burden, than
current routine care (without urodynamics).
Research suggests that the majority (90%) of men
aged 50 to 80 years suffer from at least one lower
urinary tract symptom. These symptoms increase with
age and relate to a spectrum of urinary problems
both in the storage phase (increased daytime urinary
frequency, nocturia, urgency, incontinence) and the
voiding phase (slow stream, intermittency, hesitancy,
straining and dribbling) [2]. Voiding LUTS may be
caused by either bladder dysfunction caused by poor
expulsion strength of bladder muscle or benign pros-
tate obstruction (BPO). Prostate surgery such as
transurethral resection of the prostate (TURP) is an
invasive procedure which sometimes causes unpleas-
ant adverse events, such as incontinence and difficul-
ties with sexual function [1]. A large proportion of
men suffering from BPO have improved LUTS after
surgery; however, for those with bladder dysfunction
this procedure is deemed unnecessary and potentially
harmful [1]. Estimates from hospital audit data sug-
gest that between 18% and 28% of the men currently
undergoing prostate surgery for LUTS do not have
BPO; such men are at risk of undergoing potentially
unnecessary surgery [1].
Urodynamics is a diagnostic test that can ascertain
whether BPO is present and therefore indicate
whether the patient may benefit from surgery or not
[3]. It is anticipated that use of this diagnostic tool
will reduce surgery rates (the key secondary outcome)
and this, along with the primary outcome, Inter-
national Prostate Symptom Score (IPSS) score, will be
measured 18 months after randomisation. The trial
will cover many aspects of the men’s treatment and
recovery with a clinical, cost-effectiveness and qualita-
tive analysis. If the intervention group yield a similar
symptom burden to those under usual care and the
surgery rates are reduced then this may warrant
consideration of the test becoming a more prominent
feature in the assessment pathway for men with
LUTS.
This analysis plan was written and finalised by the
trial team during the recruitment period for UP-
STREAM. Original drafts began in January 2015 with
a version finalised in September 2016. Content has
been approved by the Independent Data Monitoring
Committee (IDMC) and Trial Steering Committee
(TSC) chairs. Although one DMC report had already
been created and presented prior to this final version,
no 18-month data were available and all statisticians
and members of the DMC remained blinded to the
trial arm allocation. No formal statistical analyses
have been conducted thus far.
Methods/design
The IPSS score
The primary outcome will be measured using the IPSS,
originally known as the American Urological Association
symptom index for benign prostatic hyperplasia [4]. The
scale ranges from 0 to 35, where higher scores indicate
more severe symptoms. It comprises seven sections
scored on a scale of 0 to 5 with 0 referring to “not at all”
and 5 referring to “almost always”. These seven sections
are “incomplete emptying”, “frequency”, “intermittency”,
“urgency”, “weak stream”, “straining” and “nocturia”. To
put this into perspective a recent study found men with
voiding symptoms, storage symptoms and no symptoms
to have IPSS scores of 16.8, 14.6 and 8.5, respectively
[5]. The IPSS questionnaire also includes a quality of
life (QoL) measure which asks how patients would
feel if their urinary conditions remained the same for
the rest of their life. This ranges from 0 to 6 where 0
is “delighted” and 6 is “terrible”. The IPSS question-
naire is used at baseline, 6, 12 and 18 months. For
the sensitivity analysis, if men are missing a baseline
questionnaire, 6-month scores may substitute baseline
scores if men have not received treatment before
6 months. If men are missing 18-month scores then
the 12-month scores may substitute 18-month scores
if men have received all allocated treatment by this
time point.
Objective
This trial investigates the research question: “Is a care
pathway including urodynamics no worse for men, in
terms of symptom outcome, than routine care (with-
out urodynamics) at 18 months after randomisation”.
The null hypothesis is that the routine care is super-
ior to urodynamics while the alternative hypothesis is
that urodynamics is non-inferior to routine care. The
IPSS score will be used to calculate this:
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H0 : μroutine care–μurodynamics ≤‐1
H1 : μroutine care–μurodynamics > ‐1
For example, if the mean IPSS score for the uro-
dynamics arm is 17 at 18 months and the mean score
for the routine care arm is 15, the urodynamics arm will
be considered inferior. Conversely, if the IPSS score for
the urodynamics and routine care arms were 17.5 and
17, respectively, then urodynamics would be considered
non-inferior. As a main secondary outcome it will also
establish whether “inclusion of urodynamics reduces
rates of bladder outlet surgery, compared with routine
care”. All analyses will be based on the questionnaire
and consultation data collected at the 18-month follow-
up consultation. This time frame should allow enough
time for the urodynamics procedure, transurethral resec-
tion of the prostate, additional treatments and recovery
from these procedures.
Non-inferiority margin
Non-inferiority trials are particularly helpful when
you are testing whether a new treatment is no worse
than the current routine treatment by more than an
acceptable amount. This is often the case when inves-
tigators believe that the new treatment may offer
other advantages over the comparator treatment, e.g.
safety, costs [6]. To fully appreciate the reasoning be-
hind choosing to conduct a non-inferiority trial it is
important to understand the research questions be-
hind the primary and secondary outcomes. The key
secondary outcome will be the proportion of men
who have surgery. In the event that this is reduced,
as anticipated in the urodynamics arm, this could re-
duce unnecessary surgical interventions for men who
are suffering from LUTS which is not attributable to
BPO. Should this be the case, it is then important to
establish whether this change does not worsen patient
symptoms. With this in mind, a non-inferiority
approach was chosen to establish whether including
urodynamics leads to outcomes which are not inferior
(rather than equivalent) to a pathway without uro-
dynamics. For the primary outcome, a difference in
LUTS score of 1 point (on the IPSS scale) was con-
sidered non-inferior. The trial team felt that a 1 point
non-inferiority margin was appropriate with the fol-
lowing justification:
– A difference of 3 points and 0.5 points on the total
IPSS score and QoL IPSS score, respectively,
indicates a minimally clinical important difference
(MCID) for the overall urinary condition [7].
While this is the case for the overall IPSS score, a
difference of < 3 may involve substantial changes in
symptom bother associated with a certain subscale
[8], especially in relation to storage-type LUTS.
Given this MCID the team felt that a substantial yet
conservative estimate was needed below this figure.
– One void per night does not generally prove a
problem for patients whereas two or more is
considered substantially “bothersome” by most
patients [9]. Given that a 1-point difference on the
IPSS scale could indicate a difference in nocturia of
2 to 1 the team considered this to be a significant
turning point on the IPSS scale.
– The trial team felt that a 1-point difference was a
conservative estimate and, given this, would avoid
false claims of non-inferiority. This margin will be
explored using the bothersome measures in the
International Consultation on Incontinence Modular
Questionnaire Male Lower Urinary Tract Symptoms
(ICIQ-MLUTS) [10].
Sample size calculation
The sample size calculation was constructed from both
the primary and key secondary outcomes. For the pri-
mary outcome, IPSS score at 18 months, the trial needed
to detect a non-inferiority margin of 1 point. Using
STATA v14.1 [11], calculating a one-sided t test with a
common standard deviation of 5, mean difference of 1,
80% power and 5% alpha level, the required sample size
was 310 men per arm. It was estimated that 20%
attrition would occur due to withdrawals and losses to
follow up. Adjusting for this led to an increased sample
size of 388 per arm, 776 in total.
The key secondary outcome of surgery rate per arm
was a superiority hypothesis where the team had antici-
pated a difference in surgery rates between the arms.
Data from hospital audit indicated that 73–83% of men
presenting with LUTS were having surgery [1]. Had the
urodynamics test been conducted on the same men, the
data indicate that only 60% would have had surgery
based on the prevalence of impaired bladder contractility
contraindicating surgery. In order to show an absolute
risk reduction in surgery from 73% to 60% in the inter-
vention arm (relative risk reduction = 18%), a total of
291 men would be needed in each group. This calcula-
tion was based on a two-sided 5% significance level and
90% power. Inflating the sample size to account for 20%
attrition increased the sample size to 364 per arm, 728
in total. Thus to have sufficient power for both hypoth-
eses the trial aimed to recruit 800 men in total, around
400 men per arm.
Baseline characteristics
Baseline characteristics will be compared between the
two arms by reporting relevant summary statistics in
order to determine whether any potentially influential
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imbalance occurred, by chance, between the two arms.
Characteristics will be reported as means (SD), medians
(IQR) or proportions (percentage) depending on the
nature and distribution of the data. P values will not be
reported for differences between the two groups at base-
line, since appropriate randomisation methods will have
accounted for this. Therefore, any differences identified
would be due to chance such that a significant p value
would in reality be representative of a type 1 error (a re-
jection of the null hypothesis of no relationship when it
is in fact true). Large differences at baseline (more than
half a SD for continuous variables or 10% for categorical
variables) will be investigated in a sensitivity analysis.
The following baseline measures will be recorded and
compared: age, centre, ethnicity, Index of Multiple
Deprivation (based on postcode), comorbidities, digital
rectal examination (DRE) findings (e.g. benign enlarge-
ment), maximum flow rate (ml/s), post void residual
volume (ml), voided volume (ml), additional tests (e.g.
cystoscopy), IPSS and QoL score, ICIQ-MLUTS and
International Consultation on Incontinence Question-
naire - Sexual Matters associated with Lower Urinary
Tract Symptoms (ICIQ-MLUTSsex).
Primary analyses
The primary analysis will be conducted under the
intention to treat (ITT) principle using a linear regres-
sion model. To test the robustness of the results we will
use the per-protocol principle in a sensitivity analysis.
The dependent variable will be the overall IPSS at
18 months post randomisation. The tested null hypoth-
esis is that a treatment pathway with urodynamics is in-
ferior to a treatment pathway without urodynamics
(routine care). The mean difference will be presented
with the 95% confidence interval, adjusted for the base-
line IPSS score and centre. The difference will be calcu-
lated as the mean IPSS score in routine care minus the
mean IPSS score in urodynamics. After adjustment for
centre and baseline IPSS score, urodynamics will be
classed as non-inferior if the lower band of the 95% con-
fidence interval lies above minus one. Should the lower
confidence interval band exceed both minus one and
zero then we may test whether urodynamics is superior
to routine care, as testing for non-inferiority before
superiority does not require a statistical penalty for
multiple testing [12].
Secondary analyses
Similar to the primary analysis model, all secondary
analyses will be on an intention to treat (ITT) basis,
adjusting for centre and baseline measures (if applicable)
for the following outcomes:
1. Surgery rate at 18 months (key secondary): using
logistic regression, we will be estimating the
difference in surgery rates between the groups. It
was hypothesised that the urodynamics procedure
would reduce “unnecessary” further intervention and
therefore surgery rate, in the intervention arm.
2. Adverse events due to testing and/or treatment at
18 months: all adverse events will be compared
between the groups at 18 months; including
treatment-related and unrelated adverse events and
deaths. The number of cases of acute urinary
retention will also be examined. These will be
analysed according to the number of events
altogether and the number of events per patient.
Logistic and ordinal logistic regression will be used
to compare the groups.
3. Measures from the ICIQ [10] (ICIQ-MLUTS, ICIQ-
MLUTSsex) and IPSS QoL at 18 months: alongside
the IPSS score, the IPSS QoL and ICIQ measures
will offer a more detailed analysis of LUTS in terms
of severity, bother and impact on quality of life. We
will calculate voiding and incontinence scores along
with the proportion of men with a high frequency of
voids during the day and night. We will also look at
the proportion of men with sexual dysfunction and
the effects this has on their lives. Linear and logistic
regression will be used for continuous and binary
outcomes respectively, adjusting for centre and
respective baseline measures. Non-parametric
techniques may be employed if model assumptions
are not met.
4. Maximum urinary flow rate (Qmax) at 18 months:
the urinary flow will be measured at the 18-month
follow-up clinic appointment and analysed using
linear regression, adjusting for centre and baseline
Qmax. Adjusted for baseline measures this will give
an indication of how well a man’s urinary symptoms
have improved (or worsened), at the end of their
treatment follow up.
There will be additional cost-effectiveness and qualita-
tive analysis outcomes not mentioned in this statistical
analysis plan that will present measures on QoL.
Sensitivity analyses
Sensitivity analyses will be utilised to ensure that the
primary analysis model results are robust to appropriate
adjustments and imputations. Pre-specified sensitivity
analyses include:
1. Per-protocol analysis: the per-protocol analysis
allows assessment of treatment effect among those
who received the treatment that they were assigned
to. This analysis will include patients who received
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the treatment they were assigned to (compliers).
Therefore, from those randomised to urodynamics,
if a patient did not receive the procedure they will
be removed from this analysis. Patients who received
urodynamics despite being randomised to the
routine-care arm will also be excluded. For
non-inferiority trials it is recommended that both
ITT and per-protocol analyses are reported [13].
2. Complier average causal effect (CACE) analysis: the
CACE analysis allows unbiased assessment of
treatment effect, after separating the intervention
arm into compliers and non-compliers. Alternative
approaches may be considered if the contamination
rate is high [14].
3. Mixed-effects model: through the reviewing process
of this analysis plan, it was strongly recommended
that the team use a mixed effects repeated measures
model (MMRM). The trial team anticipates that
missing data will be missing at random (MAR) and
therefore feel that MMRM is appropriate to evaluate
the difference in treatments, while accounting for
missing IPSS scores [15].
4. Imputation using 6 and 12 month scores: for those
with missing baseline scores, the 6-month IPSS score
may be used as a substitute unless any treatment has
been received prior to the 6-month questionnaire.
Similarly, for those with missing 18-month scores,
the 12-month IPSS score may be used as a
substitute. If the primary outcome has more than
15% missing data (which could benefit from
supplementation from 6 and 12 month data) we may
consider this model for our main primary analysis.
5. Imputation for missing data: missing data for the
primary outcome, assumed to be MAR will be
imputed under conservative assumptions and the
effect of missing data investigated. If the data, as
anticipated, is MAR the trial team will consider an
approach such as multiple imputation by chained
equations (MICE). In the event that the data appear
to be missing not at random (MNAR), then
alternative approaches, such as pattern mixture
model (PMM) will be adopted. The handling of
missing data will follow the principles specified in
the European Medicines Agency guidelines [16] and
any changes to the methods described here will be
fully justified in the study report and publication.
For the imputation model adopted, a pre-specified
random seed of 648 has been chosen.
6. Adjustment for clinically important confounders:
the primary analysis and key secondary analysis
will be adjusted for centre, age, comorbidities
and symptom severity (all collected at baseline)
that were pre-specified as clinically important
by the investigators.
7. Adjustment for imbalance at baseline between the
arms: to ensure that the groups are balanced in
terms of unfavourable baseline characteristics, we
will adjust for any imbalance at baseline. A
difference of 0.5 SD or 10% between the descriptive
data will be considered an imbalance.
8. Adjustment for time between surgery and the
18 month time point: the primary outcome - IPSS
score at 18 months - is measured 18 months after
randomisation. It was originally hoped that this
would allow a 6-month “post-surgery” gap to allow
us to see the long-term effects of surgery. However,
given the nature of surgery waiting lists we will be
adjusting for “time since surgery”’ as a sensitivity
analysis to avoid spurious results caused by
symptoms retained from recent surgery.
If any of the sensitivity analyses prove important they
may be used for the secondary outcomes.
Subgroup analyses
Formal tests of interaction between the dichotomised
variables and treatment pathway will be carried out to
test whether treatment effect differ between different pa-
tient groups. Interaction tests are likely to be underpow-
ered, therefore emphasis will be placed on the point
estimates and confidence intervals generated, rather than
any associated p values. These will be at the 10% alpha
level and interpreted as hypothesis generating, as any
formal testing will be unreliable. They will be applied
to the primary analysis (IPSS score) and the main
secondary analysis (surgery rates), including (but not
limited to):
1. Age (above and below the median)
2. Flow rate (>12 ml/s vs. ≤12 ml/s)
3. Maximum voided volume (<200 ml vs. ≥200 ml),
measured in the baseline bladder diary
4. Storage dysfunction: nocturia (yes vs. no)
5. Severity of storage LUTS (more substantial vs. less
substantial)
Presentation of figures and tables
When publishing the trial results, Figure 1 will depict
the trial flow (Consolidated Standards of Reporting Tri-
als (CONSORT)) diagram, identifying the numbers of
patients who were ineligible, who declined, withdrew,
were lost to follow up or were excluded from the ana-
lysis (e.g. due to missing questionnaire data). Table 1 will
offer proportions (percentage), means (SD) or medians
(IQR) of the baseline covariates for those in the UP-
STREAM trial, by arm. If adequate data are collected we
will also compare baseline characteristics between those
who entered the study and those who declined or were
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ineligible. The primary, secondary, sensitivity and sub-
group analyses will all be presented in tables with differ-
ence estimates, confidence intervals and p values. It is
anticipated that different centres may interpret urody-
namic results differently, potentially affecting surgery
rates. Therefore, estimates will be adjusted for the base-
line measure in the question and the centre. Adverse
events will be differentiated by arm and by relation to
treatment, and graded using the Clavien-Dindo [17]
classification for surgery-based events. An independent
reviewer will assess the assigned relation to treatment
and the Clavien-Dindo scoring of surgery-related adverse
events.
Discussion
Following on from the protocol this paper aims to
add a layer of specificity to the UPSTREAM trial, to
prevent biased and misleading statistical inferences.
However, in the event that the analytical tests we
have pre-specified are not appropriate for the final
data, then alternative approaches may be considered
and full justification given.
When UPSTREAM comes to publication, an unbiased
and informed overview of pathways for men with LUTS
should result. In order to do this it is necessary to be
sure that the conclusions drawn are robust and not due
to statistical multiplicity. The trial team has defined, a
priori, both a primary and key secondary outcome on
which they based their sample size. We are not powered
to test our secondary analyses and will therefore inter-
pret any p values with due caution. This field of medi-
cine is relatively unexplored, offering numerous but
potentially sceptical observers, therefore the primary
analysis details have been set out in advance of recruit-
ment end.
Differences between the protocol and the statistical
analysis plan
This analysis plan is very similar to the protocol
published in December last year with only a few minor
changes. In the protocol abstract we stated that the aim
of the trial was to “determine whether a care pathway
not including invasive urodynamics is no worse for men
in terms of symptom outcome than one in which it is
included”, at 18 months after randomisation. Given that
this a non-inferiority trial and urodynamics is the inter-
vention we are testing, this should have read “determine
whether a care pathway including invasive urodynamics
is no worse for men in terms of symptom outcome than
one in which it is not included”. However, our non-
inferiority margin has not changed and we are still
classing a one-point difference on the IPSS scale as non-
inferior, as mentioned in the “Statistics and data
analysis” section of the published trial protocol.
Originally in the protocol paper it was stated that ran-
domisation would be stratified by centre. UPSTREAM in
fact, uses a “simple randomisation”’ approach whereby
centres utilise an automated web/telephone randomisa-
tion system provided by the Bristol Randomised Trials
Collaboration (BRTC). Since publishing the protocol
paper the trial has also received funding for a 6-month
extension, which will now mean that recruitment will
end in December and the trial will officially end in
September 2018.
Analysis of primary and secondary outcomes remains
unchanged. However, the subgroup analyses have been
updated and some sensitivity analyses added. Originally,
we had included factors that could only be found in the
urodynamics arm (e.g. whether or not the patient was
suffering from BPO). After careful consideration these
were moved to exploratory analyses. All subgroups listed
in this update can be found in both arms of the study
and will therefore be used in an interaction term in the
primary and key secondary analyses.
Trial status
This manuscript was submitted before recruitment ended
(14 December 2016) and underwent minor revisions,
based on reviewers’ feedback, after recruitment had ceased
(23 of May 2017).
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